Lp(a) With CCTA Assessed Parameters and Clinical Outcomes

Association of Lipoprotein (a) With Coronary CTA Assessed High Risk Coronary Disease Attributes and Cardiovascular Outcomes

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05323227

Acronym

CHART-ACCORD

Enrollment

378

Registered

2022-04-12

Start date

2016-03-20

Completion date

2022-05-30

Last updated

2022-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

Lipoprotein(a) \[Lp(a)\] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. This study evaluated the relationship between Lp(a) and high-risk attributes (HRA) by coronary computed tomography angiography (CCTA) as well as their prognostic value.

Interventions

DIAGNOSTIC_TESTCoronary CTA

Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with Lp(a) meaured within 1 week of CCTA examination.

Exclusion criteria

* unstable angina pectoris * acute myocardial infarction * New York Heart Association class III-IV heart failure * with a history of bypass surgery * active infection * respiratory failure * chronic kidney disease (estimated glomerular filtration rate \[eGFR\] \<60 ml/min/1.73 m2) * liver dysfunction (liver enzyme \>3 upper reference limit \[URL\] or bilirubin \>2 URL) * malignancy * systemic connective tissue disease * poor CCTA imaging quality not suitable for analysis * other situations not suitable for the study

Design outcomes

Primary

Measure	Time frame	Description
Association of Lp(a) level with CCTA measured Parameters	at the index procedure	Association of Lp(a) level with CCTA measured total plaque volume
Major adverse cardiac events	at 24 months from index procedure	a composite of cardiac death, any myocardial infarction, and stroke

Secondary

Measure	Time frame	Description
Cardiac death	at 24 months from index procedure	Cardiac death
Myocardial infarction	at 24 months from index procedure	Myocardial infarction
Stroke	at 24 months from index procedure	stroke

Countries

China

Contacts

Primary ContactNeng Dai, MD

niceday1987@hotmail.com+8613701997266

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026